---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045373"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:28:27.865272+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q3 2024 net loss $2.5M; cash $9.6M, trial interim analysis targeted late 2024/early 2025

## Summary
- Net loss of $2.5M in Q3 2024 vs $1.4M loss in Q3 2023; R&D flat at $1.7M, G&A down to $1.2M.
- Cash $9.6M at Sept 30, sufficient to fund next TIGeR-PaC interim analysis and current RenovoCath commercialization.
- Phase III TIGeR-PaC trial in LAPC: next interim analysis triggered by 52nd event (estimated late 2024/early 2025); full enrollment expected H1 2025.
- RenovoCath commercialization progressing; increased production with Medical Murray; potential near-term revenue in 2025 via direct or partner channels.
- Promoted Robert Strasser to VP R&D & Operations; enrolled first patient at University of Nebraska Medical Center for TIGeR-PaC trial.

## SEC filing metadata
- accession: 0001493152-24-045373
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315224045373/0001493152-24-045373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315224045373/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045373
- JSON: https://secwatch.observer/filing/0001493152-24-045373.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.